The Supera™ Peripheral Stent System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery with reference vessel diameters of 4.0 to 6.5 mm, and lesion lengths up to 140 mm.
The Supera™ Peripheral Stent System is contraindicated in:
patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system
patients who cannot receive antiplatelet or anticoagulation therapy. Based on in vivo thrombogenicity testing, the device should not be used in patients who cannot be anticoagulated as there may be some thrombus formation in the absence of anticoagulation.
This device is intended for single-use only. Do not reuse. Do not resterilize. Do not use if the package is opened or damaged.
Use this device prior to the “Use By” date as specified on the device package label. Store in a dry, dark, cool place.
DO NOT use if it is suspected that the sterility of the device has been compromised.
Persons with known hypersensitivities to Nitinol and / or its components (e.g. nickel titanium) may suffer an allergic reaction to this implant.
Administer appropriate antiplatelet therapy pre- and post-procedure.
Careful attention should be paid when sizing and deploying the stent to prevent stent elongation. In the SUPERB clinical study, stent elongation was associated with a decrease in patency at 12 months.
The Supera™ Peripheral Stent System should only be used by physicians and medical personnel trained in vascular interventional techniques and trained on the use of this device.
The long-term safety and effectiveness of the Supera™ Peripheral Stent System has not been established beyond three years.
The safety and effectiveness of the Supera™ Peripheral Stent System has not been established in patients who:
are less than 18 years old
are pregnant or lactating
have in-stent restenosis of the target lesion
have known hypersensitivity to any component of the stent system (e.g., nickel)
cannot tolerate contrast media and cannot be pre-treated
have uncontrolled hypercoaguability and / or other coagulopathy
This device is not designed for use with contrast media injection systems or power injection systems.
The flexible design of the Supera™ Stent may result in variation in the deployed stent length.
Magnetic Resonance Imaging (MRI)
A patient with this device can be scanned safely only under specific conditions. Failure to follow the conditions may result in severe injury.
Non-clinical testing has demonstrated the Supera™ Stents are MR Conditional for lengths up to 250 mm. A patient with this stent can be scanned safely, immediately after placement, under the following conditions:
Static magnetic field of 1.5 or 3.0 Tesla
Highest spatial gradient magnetic field of 2,500 Gauss/cm or less
Maximum MR whole-body-averaged specific absorption rate (SAR) of
2 W/kg for landmarks (i.e. center of RF coil) above the umbilicus
1 W/kg for landmarks below the umbilicus and above the mid-thigh
0.5 W/kg for landmarks below the mid-thigh for 15 minutes of scanning (per pulse sequence), operating in the Normal Operating Mode (i.e., MR system mode of operation where there is no physiological stress to the patient). The legs of the patient should not be touching during the procedure.
POTENTIAL ADVERSE EVENTS:
Potential adverse events include, but are not limited to:
Allergic reaction (contrast medium; drug; stent material)
Amputation or limb loss
Aneurysm or pseudoaneurysm in vessel or at vascular access site
Angina or coronary ischemia
Arrhythmia (including premature beats, bradycardia, atrial or ventricular tachycardia, atrial or ventricular fibrillation)
Bleeding complications requiring transfusion or surgical intervention
Detachment of a system component or implantation in an unintended site
Embolization, arterial or other (e.g. air, tissue, plaque, thrombotic material, or stent)
Hematoma or hemorrhagic event, with or without surgical repair
Hypertension / Hypotension
Pain (leg, foot, and/or insertion site)
Partial stent deployment
Peripheral nerve injury
Renal failure or insufficiency
Restenosis of vessel in stented segment
Stent malapposition or migration, which may require emergency surgery to remove stent
Stent strut fracture
Thrombosis or occlusion
Transient ischemic attack
Vessel dissection, perforation or rupture
Vessel spasm or recoil
Worsening claudication or rest pain
This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.